ClinicalTrials.gg
Not yet recruitingNCT07254637TociCCAreUpdated Nov 17, 2026

Tocilizumab in Chronic Inflammatory CPPD Disease

A Phase 2 interventional study of Tocilizumab and Placebo in Calcium Pyrophosphate Deposition Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.

The main questions this trial aims to answer are:

  • Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease?
  • Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease?

Participants will receive a monthly infusion of tocilizumab or placebo for three months.

Read the detailed description

Calcium pyrophosphate deposition (CPPD) disease affects 4 to 7% of the adult population. CPP crystals are responsible for inflammatory flares affecting one or more joints. The inflammation triggered by CPP crystals resembles that associated with sodium urate crystals in gout and depends on inflammatory cytokines such as interleukins (IL-) 1β and -6. The usual treatments are those used in gout flares (colchicine, NSAIDs, corticosteroids, IL-1β inhibitors), and most often control monoarticular involvement. The chronic inflammatory polyarticular form, on the other hand, is more difficult to treat, causing significant pain and disability, as well as joint destruction. In refractory forms, or in cases of intolerance to standard treatments, alternative therapies are required. In this context, the investigators treated 11 patients with refractory chronic inflammatory CPPD with tocilizumab (TCZ), an anti-IL-6 receptor (IL-6R) monoclonal antibody. After 3 monthly infusions, improvement was estimated at over 75% (PMID 2213498). Our hypothesis is that inhibiting IL-6 is an effective therapeutic option in chronic inflammatory CPPD refractory to conventional therapies.

Main objective and primary endpoint:

  • To demonstrate the efficacy of IL-6 inhibition in treatment-refractory chronic inflammatory forms of CPPD disease.
  • Our endpoint will be the change in global pain VAS between initiation and M4, i.e. one month after the 3rd infusion. VAS will be assessed after 24 hours off analgesics.

Secondary objectives and endpoints:

  • Efficacy: DAS28-CRP, number of swollen, painful joints, overall disease activity VAS, fatigue VAS; overall effect on pain: area under the VAS curve (AUC); proportion of patients responding from M2 to M6 (improvement ≥ 50% of initial pain VAS) and complete response (improvement ≥ 80% of initial pain VAS); relapse rate; improvement in quality of life (SF-36, HAQ, EQ-5D-3L questionnaires)
  • Tolerance: infusion reactions, infections, neutropenia, hepatic cytolysis, lipid profile

This is a phase II, multicentre, randomized, controlled, double-blind, superiority study, including 2 parallel groups with a 1:1 distribution. This trial will involve adults suffering from the chronic inflammatory polyarticular form of CPPD disease.

This study will involve 80 participants recruited in 13 centres in France.

02

Conditions studied

  • Calcium Pyrophosphate Deposition Disease
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults > 18 years
  • Diagnosis of CPPD according to ACR/EULAR 2023 classification criteria
  • Persistent inflammatory pain (> 3 months) or ≥ 2 arthritics/month
  • Number of painful joints (NAD) > 3
  • Overall pain VAS (0_100) > 40 mm
  • Failure, intolerance or impossibility of repeated use of usual treatments: colchicine, NSAIDs, and anakinra
  • Use of an effective method of in women of childbearing age until 3 months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of anti-CPP antibodies > 50 IU/ml
  • Recurrent or chronic infections
  • History of severe infection (= requiring hospitalization)
  • Active infection
  • Vaccination with live or attenuated vaccine within 4 weeks prior to inclusion
  • History of intestinal ulceration or diverticulitis Untreated latent tuberculosis
  • History of viral ou C
  • Symptoms suggestive of demyelinating disease of the central nervous system
  • History of cancer, active cancer, or suspected cancer
  • Neutropenia \< 2000 elements/mm3, thrombocytopenia \< 100 000/mm3
  • Elevated transaminases > 3 x
  • Known to the active substance or one of the ;
  • Known severe immune deficiency
  • Patients not meeting classification criteria
  • Concomitant treatment with biological or targeted therapies, or therapy (including methotrexate, leflunomide, azathioprine), systemic , anakinra, IL-6 inhibitors in subcutaneous injection, anti-TNF agents, and JAK. If these treatments are used before inclusion, a corresponding to at least five times their respective mean terminal half-life must be respected.
  • inhibitors.
  • Previous treatment with tocilizumab
  • Concomitant treatment with methylprednisolone, dexamethasone, atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, cyclosporine or benzodiazepines
  • Dyslipidemia, hypertension or poorly controlled cardiovascular disease
  • Scheduled surgery
  • Difficulty to understand French, illiteracy
  • Pregnant women, women in labor or nursing mothers
  • Persons deprived of their liberty, adults under legal protection or unable to express their consent
  • Persons not affiliated to a social security scheme or beneficiaries of such a scheme
  • Participation in another interventional study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Tocilizumab

    Drug: Tocilizumab

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Tocilizumab, 8 mg/kg/month, IV infusion for 3 months Tocilizumab, an anti-IL-6R monoclonal antibody, was approved in January 2009 for the treatment of rheumatoid arthritis. Its indications have since been extended, particularly for the treatment of giant cell arteritis, juvenile chronic arthritis, and severe cytokine release syndrome induced by chimeric antigen receptor T-cell (CAR-T) therapy.

  • OtherPlacebo

    Saline placebo, IV infusion / month for 3 months

06

What researchers measure

Primary outcomes

  1. Change in overall pain VAS

    Overall pain will be assessed, after 24 hours of discontinuation of analgesics, using a visual analogue scale (VAS) ranging from 0 (no pain) to 100 mm (worst pain ever experienced), at inclusion, before each infusion at months M1, M2, M3, then at M4 (primary outcome) and M6.

    Time frame: 6 months

Secondary outcomes

  1. Change in the number of swollen and tender joints

    Disease Activity Score (DAS28-CRP), number of swollen and painful joints, Patient assessment of overall disease activity by a visual analogue scale (VAS) ranging from 0 (no activity) to 100 mm (maximal activity). Those outcomes will be assessed at inclusion, before each infusion at months M1, M2, M3, then at M4 (primary outcome) and M6

    Time frame: 6 months

  2. Overall effect on pain

    Area under the curve (AUC) of the overall pain visual analogue scale (VAS) ranging from 0 (no pain) to 100 mm (worst pain ever experienced) based on assessments at baseline, before each infusion at months M1, M2, M3 and at M4 and M6 (end of the study). Overall pain VAS will be collected after a 24-hour washout of analgesics.

    Time frame: 6 months

  3. Response to treatment / relapse

    Response to treatment will be defined as an improvement ≥ 50% of initial pain visual analogue scale (VAS) ranging from 0 (no pain) to 100 mm (worst pain ever experienced) Complete response will be defined as an improvement ≥ 80% of initial pain VAS This outcome will be assessed from M2 to M6. Relapse will be assessed in responders at 6 months, and the time from response to relapse will be determined.

    Time frame: 6 months

  4. Flares (ESR)

    Outcome Measures - Inflammatory Biomarkers Erythrocyte Sedimentation Rate (ESR) Unit: millimeters (mm) Frequency: measured at each visit No aggregation of this measure is planned to produce a composite value. If aggregation is considered (e.g., to generate an overall inflammation score), a validated statistical method will be specified.

    Time frame: 6 months

  5. Flares (CRP)

    Outcome Measures - Inflammatory Biomarkers C-reactive Protein (CRP) Unit: milligrams per liter (mg/L) Frequency: measured at each visit No aggregation of this measure is planned to produce a composite value. If aggregation is considered (e.g., to generate an overall inflammation score), a validated statistical method will be specified.

    Time frame: 6 months

  6. Flares (IL-6)

    Outcome Measures - Inflammatory Biomarkers Interleukin-6 (IL-6) Unit: picograms per milliliter (pg/mL) Frequency: measured at each visit No aggregation of this measure is planned to produce a composite value. If aggregation is considered (e.g., to generate an overall inflammation score), a validated statistical method will be specified.

    Time frame: 6 months

  7. Quality of life's Questionnaires (SF-36)

    Full Title: Short Form 36 Health Survey (SF-36) Scale Range: 0 to 100 per subscale Interpretation: Higher scores indicate better health status or quality of life Time Points: Baseline, prior to each infusion, and at Months 4 and 6 (M4 and M6) Unit: Score This questionnaire will be analyzed and reported as a distinct outcome measure, in accordance with its specific scoring system.

    Time frame: 6 months

  8. Quality of life's Questionnaires (HAQ)

    Full Title: Health Assessment Questionnaire (HAQ) Scale Range: 0 to 3 Interpretation: Higher scores indicate worse functional ability (i.e., more disability) Time Points: Baseline, prior to each infusion, and at Months 4 and 6 (M4 and M6) Unit: Score This questionnaire will be analyzed and reported as a distinct outcome measure, in accordance with its specific scoring system.

    Time frame: 6 months

  9. Quality of life's Questionnaires (EQ-5D-3L)

    Full Title: EuroQol Five Dimensions Three Levels (EQ-5D-3L) Scale Range: 0 to 100 Interpretation: Higher scores indicate better health-related quality of life Time Points: Baseline, prior to each infusion, and at Months 4 and 6 (M4 and M6) Unit: Index value This questionnaire will be analyzed and reported as a distinct outcome measure, in accordance with its specific scoring system.

    Time frame: 6 months

  10. Patient Safety - Number of Participants with Adverse Events

    Outcome Measure - Number of Participants with Adverse Events Description: Number of participants experiencing any of the following safety-related events at each visit: * Infusion reactions * Neutropenia * Thrombocytopenia * Hepatic cytolysis * Severe infections * Treatment-related adverse events * Abnormal changes in lipid profile Unit of Measure: Count (participants) Time Points: Each visit Note: Each event type will be recorded and analyzed separately but reported under a unified outcome measure to reflect overall safety.

    Time frame: 6 months

  11. Patient Safety - Number of patients with abnormal laboratory tests results - Mean Neutrophil Count

    Description: Mean neutrophil count measured from blood samples collected at each visit. Unit of Measure: normal: 2500-8000/μL; AE: \<1500/μL

    Time frame: 6 months

  12. Patient Safety - Number of patients with abnormal laboratory tests results - Mean Platelet Count

    Description: Mean platelet count measured from blood samples collected at each visit. Unit of Measure: normal: 150,000-400,000/μL; AE: \<75,000/μL

    Time frame: 6 months

  13. Patient Safety - Number of patients with abnormal laboratory tests results - Mean Transaminase Levels

    Description: Mean levels of transaminases (e.g., ALT, AST) measured to assess hepatic cytolysis. Unit of Measure: ALT/AST normal: \<40 U/L; AE: \>3×ULN

    Time frame: 6 months

  14. Patient Safety - Number of patients with abnormal laboratory tests results - Mean Lipid Profile Values

    Description: Mean values of lipid profile components (e.g., total cholesterol, LDL, HDL, triglycerides) measured at each visit. Unit of Measure: normal: TC \<200, LDL \<130, HDL \>45/55, TG \<150 mg/dL

    Time frame: 6 months

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Apr 2026 → Nov 2026 and primary completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Nov 28, 2025
StartEst.
Nov 2026was Apr 2026
Primary completionEst.
Nov 2026was Oct 2026
CompletionEst.
Nov 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 10 sites removed
Show 11 added (11 France)
  • Hôpital NOVO · Pontoise, France
  • CHU de Dijon · Dijon, France
  • CHU de Nantes · Nantes, France
  • Hôpital Bichat Claude-Bernard · Paris, France
  • Hôpital de la Croix Saint-Simon · Paris, France
  • Hôpital Tenon · Paris, France
  • Groupe Hospitalier Intercommunal Le Raincy-Montfermeil · Paris, France
  • Hôpital Le Kremlin Bicêtre · Paris, France
  • Hôpital NOVO · Pontoise, France
  • CHU de Rennes · Rennes, France
  • CHU de Saint-Étienne · Saint-Etienne, France
Show 10 removed
  • CHU de Dijon · Dijon, France
  • CHU de Nantes · Nantes, France
  • Hôpital Bichat Claude-Bernard · Paris, France
  • Hôpital de la Croix Saint-Simon · Paris, France
  • Hôpital Tenon · Paris, France
  • Groupe Hospitalier Intercommunal Le Raincy-Montfermeil · Paris, France
  • Hôpital Le Kremlin Bicêtre · Paris, France
  • Hôpital NOVO · Pontoise, France
  • CHU de Rennes · Rennes, France
  • CHU de Saint-Étienne · Saint-Etienne, France
across 2 updates, Nov 10, 2026 – Nov 17, 2026
Start date
Apr 2026→Nov 2026
Nov 10, 2026
Primary completion
Oct 2026→Nov 2026
Nov 10, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange in the number of swollen and tender joints: how it is measured was reworded
Nov 10, 2026
Show all 2 updates
  1. Nov 17, 2026
    10 sites added, 10 sites removed
    Show 10 added (10 France)
    • CHU de Dijon · Dijon, France
    • CHU de Nantes · Nantes, France
    • Hôpital Bichat Claude-Bernard · Paris, France
    • Hôpital de la Croix Saint-Simon · Paris, France
    • Hôpital Tenon · Paris, France
    • Groupe Hospitalier Intercommunal Le Raincy-Montfermeil · Paris, France
    • Hôpital Le Kremlin Bicêtre · Paris, France
    • Hôpital NOVO · Pontoise, France
    • CHU de Rennes · Rennes, France
    • CHU de Saint-Étienne · Saint-Etienne, France
    Show 10 removed
    • CHU de Dijon · Dijon, France
    • CHU de Nantes · Nantes, France
    • Hôpital Bichat Claude-Bernard · Paris, France
    • Hôpital de la Croix Saint-Simon · Paris, France
    • Hôpital Tenon · Paris, France
    • Groupe Hospitalier Intercommunal Le Raincy-Montfermeil · Paris, France
    • Hôpital Le Kremlin Bicêtre · Paris, France
    • Hôpital NOVO · Pontoise, France
    • CHU de Rennes · Rennes, France
    • CHU de Saint-Étienne · Saint-Etienne, France
  2. Nov 10, 2026
    1 site added
    Show site
    • Hôpital NOVO · Pontoise, France
    Start date Apr 2026→Nov 2026
    Primary completion Oct 2026→Nov 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in the number of swollen and tender joints: how it is measured was reworded
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07254637
Collaborators
Fresenius AG
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Nov 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Augustin Latourte, Associate Professor
Contact
augustin.latourte@aphp.fr
+33 1 49 95 62 90

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion